» Articles » PMID: 15234290

Classification of Farnsworth-Munsell 100-hue Test Results in the Early Treatment Diabetic Retinopathy Study

Overview
Journal Am J Ophthalmol
Specialty Ophthalmology
Date 2004 Jul 6
PMID 15234290
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To classify and describe clinically meaningful classes of color vision defects using pretreatment Farnsworth-Munsell 100-hue results from the Early Treatment Diabetic Retinopathy Study (ETDRS) patients using standard statistical techniques.

Design: The ETDRS was a randomized trial investigating retinal photocoagulation and oral aspirin in diabetic retinopathy.

Methods: Farnsworth-Munsell (FM) 100-hue test was successfully administered before initiation of study treatment in each eye of 2701 of the 3711 ETDRS patients. Test results were converted into a Fourier series, classified by cluster analysis in the deferred-treatment group of eyes, and verified in the immediate-treatment group of eyes as separate samples.

Results: Cluster analysis uncovered thirteen distinct patterns. Pattern A (51% or 1366 of the eyes) showed unimpaired hue discrimination and was comprised of younger patients with no or little macular edema. Pattern B eyes (10% or 262) showed generalized impairment of hue discrimination with no main axis defect. Patterns C (C1, C2, C3), comprising 26% (or 698) of the eyes, showed increasing severity of the yellow-blue diabetic retinopathy defect, associated with increasing mean age and increasing macular edema severity. Patterns D (D1, D2), comprising 6% (or 164) of the eyes, were similar to the C patterns but showed a stronger yellow-blue defect. Patterns E (E1, E2, E3), or approximately 2% (or 38) of the eyes and predominantly male, exhibited the expected pattern for congenital protan defect. Patterns F, G, and H, approximately 6% (or 153) of the eyes, showed distinct patterns of one-sided axes. The nomenclature is arbitrary.

Conclusions: Cluster analysis of FM 100-hue test results has found 13 patterns of impaired hue discrimination, helpful in understanding color vision defects in diabetes mellitus.

Citing Articles

Speckle Contrast as Retinal Tissue Integrity Biomarker in Patients with Type 1 Diabetes Mellitus with No Retinopathy.

Orduna-Hospital E, Arcas-Carbonell M, Sanchez-Cano A, Pinilla I, Consejo A J Pers Med. 2022; 12(11).

PMID: 36579516 PMC: 9693211. DOI: 10.3390/jpm12111807.


Changes in retinal layers in type 1 diabetes mellitus without retinopathy measured by spectral domain and swept source OCTs.

Orduna-Hospital E, Sanchez-Cano A, Perdices L, Acha J, Lopez-Alaminos E, Pinilla I Sci Rep. 2021; 11(1):10427.

PMID: 34001996 PMC: 8129145. DOI: 10.1038/s41598-021-89992-w.


New iPAD-based test for the detection of color vision deficiencies.

de Fez D, Luque M, Matea L, Pinero D, Camps V Graefes Arch Clin Exp Ophthalmol. 2018; 256(12):2349-2360.

PMID: 30291435 DOI: 10.1007/s00417-018-4154-y.


Acuity and colour vision changes post intravitreal dexamethasone implant injection in patients with diabetic macular oedema.

Abdel-Hay A, Sivaprasad S, Subramanian A, Barbur J PLoS One. 2018; 13(6):e0199693.

PMID: 29944702 PMC: 6019681. DOI: 10.1371/journal.pone.0199693.


Color vision abnormalities in type II diabetes: Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetics Study II report no 2.

Gella L, Raman R, Kulothungan V, Pal S, Ganesan S, Srinivasan S Indian J Ophthalmol. 2017; 65(10):989-994.

PMID: 29044066 PMC: 5678337. DOI: 10.4103/ijo.IJO_601_16.